The Medicines and Healthcare products Regulatory Agency (MHRA) has approved elafibranor (Iqirvo) to treat adult patients with a rare type of liver disease known as primary biliary cholangitis (PBC).
Follow this news feed:
Oct82024
Elafibranor approved to treat adults with a rare liver disease known as primary biliary cholangitis